74 related articles for article (PubMed ID: 16178987)
1. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis.
Halpin DM
Int J Clin Pract; 2005 Oct; 59(10):1187-94. PubMed ID: 16178987
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
3. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
4. Single inhaler budesonide/formoterol in exacerbations of chronic obstructive pulmonary disease.
Cazzola M
Pulm Pharmacol Ther; 2006; 19(2):79-89. PubMed ID: 15964228
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
6. Innovations to achieve excellence in COPD diagnosis and treatment in primary care.
Fromer L; Barnes T; Garvey C; Ortiz G; Saver DF; Yawn B
Postgrad Med; 2010 Sep; 122(5):150-64. PubMed ID: 20861599
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
[TBL] [Abstract][Full Text] [Related]
8. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
Pauwels RA; Löfdahl CG; Postma DS; Tattersfield AE; O'Byrne P; Barnes PJ; Ullman A
N Engl J Med; 1997 Nov; 337(20):1405-11. PubMed ID: 9358137
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark--cost-effectiveness analysis based on five randomised controlled trials.
Wickstrøm J; Dam N; Malmberg I; Hansen BB; Lange P
Clin Respir J; 2009 Jul; 3(3):169-80. PubMed ID: 20298400
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
Sin DD; Man SF
Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
[TBL] [Abstract][Full Text] [Related]
11. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Bousquet J; Boulet LP; Peters MJ; Magnussen H; Quiralte J; Martinez-Aguilar NE; Carlsheimer A
Respir Med; 2007 Dec; 101(12):2437-46. PubMed ID: 17905575
[TBL] [Abstract][Full Text] [Related]
12. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
13. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease.
Berger WE; Nadel JA
Respir Med; 2008 Feb; 102(2):173-88. PubMed ID: 18023995
[TBL] [Abstract][Full Text] [Related]
15. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
[TBL] [Abstract][Full Text] [Related]
17. Budesonide/formoterol maintenance and reliever therapy versus conventional best practice.
Demoly P; Louis R; Søes-Petersen U; Naya I; Carlsheimer A; Worth H; Almeida J; Sears MR
Respir Med; 2009 Nov; 103(11):1623-32. PubMed ID: 19762222
[TBL] [Abstract][Full Text] [Related]
18. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease.
Nichols J
Pharmacotherapy; 2007 Mar; 27(3):447-54. PubMed ID: 17316155
[TBL] [Abstract][Full Text] [Related]
19. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]